Living with IBS: A Gastroenterologist's Guide to What to Do After Diagnosis
Updated: 5 hours ago
Key points
IBS treatment: where should you start?
IBS treatment depends on whether your main problem is constipation, diarrhoea, bloating or abdominal pain. Management may involve dietary changes, soluble fibre, prescription medication, gut-directed psychological therapy or targeted investigations [4,5].
If your IBS is not getting better despite the usual treatments, a gastroenterologist can reassess the diagnosis and look for contributors that are easy to miss, such as a motility disorder, bile acid diarrhoea, pelvic floor dyssynergia or visceral hypersensitivity. That is what the approach below is designed to do.
An IBS diagnosis is a starting point, not an end point. IBS is a label for a pattern of symptoms. The real work is finding which mechanism is driving yours.
The approach matters more than any single test or treatment. I first work out whether the symptoms suggest fast, slow or normal transit, then look at three drivers: microbes, diet and gut sensitivity. Treatment follows the mechanism, not the label.
Most people with IBS have normal bowel transit. In one study, 80% had normal colonic transit [12]. For many of them, gut sensitivity matters more than bowel speed, so treatments aimed only at the bowel habit often disappoint.
Bile acids and gut microbes can speed the bowel up or slow it down, and "wheat intolerance" is more often the fructan in wheat than gluten [27,30,42].
More tests are not better tests. A breath test can reflect transit rather than bacterial overgrowth [9]. I choose each test to answer one question that will change your treatment.
Diagnosed with IBS? This is where the work starts
A diagnosis of irritable bowel syndrome (IBS) is the beginning of a journey, not the end of one. Too many patients hear "IBS" as "your tests are normal, there is nothing more we can do". In my practice, it is the point where we start working out why your bowel behaves the way it does.
IBS is common. Depending on how strictly it is defined, it affects roughly 5–10% of people at any one time [1]. A 2026 global survey using Rome V found IBS in 8.5% of adults [68]. Doctors now diagnose it with the Rome V criteria, published in 2026: recurrent abdominal pain or discomfort, on average at least three days a month over the past three months, linked to opening the bowels or to a change in how often you go or what the stool looks like, with symptoms starting at least six months earlier [2]. Compared with the older Rome IV criteria, Rome V brings back "discomfort" and lowers the frequency threshold, so it recognises more people, often with milder symptoms [69].
IBS can be diagnosed confidently from your story, an examination and a few targeted tests. A Danish trial found this "positive diagnosis" approach was as safe and accurate as a long list of exclusion tests, and cheaper [3]. Both the British and American gastroenterology guidelines now recommend it [4,5].
The catch is that IBS is a label for a pattern of symptoms, not an explanation. Two people with the same label can have completely different problems underneath. My job is to work out which mechanism is driving your symptoms, and treat that.
Most of the people I see have already been told they have IBS, sometimes years earlier. Their colonoscopy was normal, and they have usually tried a low FODMAP diet and several laxatives without lasting relief. My training shapes how I approach them. I did a fellowship in neurogastroenterology (gut motility) in Melbourne, and advanced training in microbiome medicine at the Centre for Digestive Diseases in Sydney. So I look at IBS through both lenses at once: how the gut moves, and what its microbes are doing.
My approach: from label to mechanism
This approach is the core of how I manage IBS, and it is the part most IBS guides leave out. I don't work through a fixed list of tests and treatments. Instead I ask questions in a set order, and each answer narrows the next.

Is it safe to call this IBS? A careful history and examination, blood tests and coeliac serology, plus a stool calprotectin when diarrhoea is a feature. Colonoscopy only when there are red flags.
Is the gut too fast, too slow, or normal speed? Stool form, frequency, urgency and straining give the first clue. Bowel habit is a clue, not proof, so I reserve formal transit testing for when confirming it would change treatment.
What is pushing it that way? Microbes and diet are the usual suspects. Methane-producing microbes are linked with a slower gut. Excess bile acid speeds it up, and hydrogen sulfide-producing microbes may too. Fermentable carbohydrates and the wrong fibre add water and gas.
How loud is the gut–brain "volume"? Pain or bloating out of proportion to the bowel habit points to visceral hypersensitivity. That needs its own treatment.
Which single test would change treatment now? I order only that test.
Treat in layers. First the foundation (diet, the right fibre, activity), then mechanism-specific treatment, then gut–brain therapy if needed.
Review at 6–12 weeks and adjust. IBS often has more than one driver, and peeling back one layer can reveal the next.
In clinic: two typical journeys Composite examples based on patterns I see often, not individual patients. 1. "Constipated for years, tried everything." 2. "Urgent, loose stools after meals."
Story: hard stools, straining and bloating that builds through the afternoon. Several laxatives have been tried, and the colonoscopy was normal.
Reasoning: the pattern suggests the slow lane. Straining and a feeling of incomplete emptying also raise a pelvic floor problem, and afternoon bloating raises methane.
Tests: an X-ray marker study for transit, anorectal manometry for the pelvic floor, and a methane breath test, because each answer changes treatment.
Treatment: psyllium and kiwifruit as the base. Pelvic floor biofeedback if dyssynergia is confirmed, a secretagogue for slow transit, and methane-directed treatment if methane is high. Each layer is reviewed before the next is added.
Story: symptoms began after gallbladder removal or a bout of gastroenteritis. Urgency is worst after fatty meals, and calprotectin is normal.
Reasoning: the fast lane, with bile acids as the leading suspect.
Test: a trial of cholestyramine. SeHCAT scanning is not available in Australia, and a clear response supports the diagnosis.
Treatment: the binder at the lowest effective dose, with ondansetron or loperamide for any remaining urgency.
Quick guide: where to start
Your main symptom | Likely lane | A sensible first step | Read more |
Hard, infrequent stools, straining | Slow | Psyllium, kiwifruit, macrogol | Motility |
Loose, urgent stools | Fast | Psyllium, loperamide on bad days; ask about bile acids | Microbiome and bile acids |
Bloating and wind | Diet and microbes | Low FODMAP with a dietitian, then reintroduce foods | Diet |
Pain is the main problem | Normal transit | Regular activity, peppermint oil; ask about amitriptyline or hypnotherapy | Gut–brain axis |
The full step-by-step plan is in the practical summary at the end.
The four pillars I think about
I think about IBS through four connected pillars: motility, the microbiome, diet and visceral hypersensitivity (the gut–brain axis). Most patients have problems in more than one, and each pillar pushes on the others [1].
Pillar | What it means | What goes wrong in IBS |
Motility | How fast, and how well coordinated, the gut moves its contents | Transit that is too fast (diarrhoea), too slow (constipation), or normal speed but poorly coordinated |
Microbiome | The trillions of microbes in the bowel and the chemicals they make | Fermentation by-products, methane, hydrogen sulfide and bile acid changes that speed up or slow down the gut |
Diet | What reaches the bowel and how it is digested or fermented | Fermentable carbohydrates (FODMAPs) and the wrong type of fibre draw in water and produce gas |
Visceral hypersensitivity / gut–brain axis | How the nerves in the gut and the brain process normal gut signals | Normal amounts of gas or stretch are felt as pain, bloating and urgency |
These pillars are connected. A large study that followed IBS patients over months found that different subgroups had different driving mechanisms, including altered bile acids and microbial metabolites [6]. An Australian population study followed people for 12 years and showed the gut–brain pathway runs both ways: anxiety can lead to gut symptoms, and gut symptoms can lead to anxiety [7].
Tests: solving the puzzle, not ticking every box
There are many tests for IBS, and I do not recommend doing them all. Your history and symptom pattern usually point to one or two pillars, and I choose tests that answer a specific question.
Every patient needs a safe baseline, usually blood tests and coeliac serology. When diarrhoea is a feature, I add a stool calprotectin; a level below 40 µg/g makes inflammatory bowel disease very unlikely [8]. Colonoscopy is for red flags: bleeding, weight loss, anaemia, a family history of bowel cancer or IBD, nocturnal symptoms, or a new change in bowel habit in middle age or later [4,5]. Australia's bowel cancer screening program starts at 45, but turning 45 is not by itself a reason for colonoscopy when symptoms are typical of IBS.
Beyond that, more testing is not always better. Breath tests are a good example. In one study combining scintigraphy with lactulose breath testing, a hydrogen rise in IBS mostly reflected the lactulose reaching the colon, not bacteria in the small bowel [9]. Ordered without a clear question, a breath test can lead to treatment for the wrong problem.
Motility testing is different. Scintigraphy shows abnormal colonic transit in about 30% of people with lower functional bowel disorders [10]. That makes it useful when the history does not fit, or when first-line treatment has failed.
Clue from your story | What I think about | Test I might use |
Hard, infrequent stools, straining, feeling of incomplete emptying | Slow transit or pelvic floor dyssynergia | X-ray marker study, anorectal manometry |
Loose, urgent stools, worse after fatty meals or after gallbladder removal | Fast transit, bile acid diarrhoea | A trial of cholestyramine (SeHCAT scanning is not available in Australia) |
Early fullness, nausea, bloating soon after eating | Slow stomach emptying (overlap with dyspepsia) | Gastric emptying study |
Bloating that builds through the day, symptoms after antibiotics or bowel surgery | Microbial overgrowth, methane | Breath test, interpreted carefully |
Pain out of proportion to bowel habit, stress-linked flares | Visceral hypersensitivity | Usually no test; diagnosis from the history |
Upper symptoms are worth asking about. A meta-analysis found that people with dyspepsia are about eight times more likely to also have IBS [11].
Pillar 1: Motility – is your gut too fast, too slow, or neither?
The first question I ask is whether the symptoms suggest accelerated, delayed or relatively normal transit. Stool pattern gives the first clue, and I reserve formal testing for when confirming the mechanism would change management. The answer changes treatment more than any other single finding.
Motility type | Typical symptoms | Common contributors | Treatment direction |
Hypermotility (fast transit) | Loose, urgent, frequent stools | Bile acid diarrhoea, post-infectious change, possibly hydrogen sulfide-producing microbes | Slow the gut down: bile acid binders, 5-HT3 blockers, loperamide |
Hypomotility (slow transit) | Hard, infrequent stools, bloating that builds | Methane-producing microbes, low fibre intake, pelvic floor dyssynergia | Speed the gut up: osmotic agents, secretagogues, prokinetics, pelvic floor therapy |
Normal transit | Pain and bloating out of proportion to bowel habit | Visceral hypersensitivity, gut–brain axis | Calm the nerves: neuromodulators, gut-directed hypnotherapy, diet |
Most people with IBS actually have normal transit. In a Swedish study of 359 IBS patients, colonic transit was normal in 80%, fast in 15% and slow in 5% [12]. Transit tracked closely with stool form and frequency, but not with pain or bloating [12]. That is why pain-dominant IBS usually needs a different approach from bowel-habit-dominant IBS. Bowel habit and measured transit are not the same thing, though. Someone with IBS-C can have normal transit, and normal transit does not by itself prove that gut sensitivity is the main driver.
How I assess motility
I start with your history: stool form on the Bristol scale, frequency, urgency, straining and the timing of symptoms after meals. I add a test only when the answer will change treatment.
Gastric emptying study. For early fullness, nausea or upper bloating, which overlap strongly with IBS [11].
X-ray marker (Sitzmark) study. You swallow small radio-opaque markers and an abdominal X-ray a few days later shows how many remain and where. It is simple, cheap and widely available [13].
Colonic transit scintigraphy. A more detailed nuclear medicine test of colonic transit, abnormal in about 30% of people with lower functional bowel disorders [10].
Anorectal manometry and balloon expulsion. For straining and incomplete emptying. In one specialist-clinic cohort with constipation-predominant IBS, most had dyssynergic defecation, where the pelvic floor tightens instead of relaxing [14]. Laxatives don't fix this coordination problem. In a randomised trial, five sessions of biofeedback gave major improvement in 80% of patients, compared with 22% on laxatives [15]. I studied physiotherapy before medicine, so pelvic floor retraining is close to my heart.
Motility does not work in isolation. What you eat and the microbes that ferment it change how fast the gut moves, which brings us to the next two pillars.
Pillar 2: The microbiome – the chemistry that sets the pace
Your gut microbes affect motility mainly through the chemicals they make: short-chain fatty acids, gases such as methane and hydrogen sulfide, and modified bile acids. People with IBS have a different microbiome from healthy controls, but there is no single "IBS microbiome" [16]. What matters is which of these chemical pathways is out of balance in you.
Short-chain fatty acids (SCFAs)
When bacteria ferment fibre, they produce SCFAs: acetate, propionate and butyrate. SCFAs trigger serotonin release from the gut lining, which sped up colonic transit in animal studies [19]. Gut bacteria also directly regulate how much serotonin the gut makes [20].
The pattern fits the clinic. A meta-analysis found lower propionate and butyrate in constipation-predominant IBS, and higher butyrate in diarrhoea-predominant IBS [18]. Very high acetate and propionate levels have also been linked to worse pain and bloating [17]. A working hypothesis is that too little fermentation slows the gut, and too much speeds it up and causes symptoms. This is not yet proven in people.
Methane and intestinal methanogen overgrowth (IMO)
Some microbes, mainly Methanobrevibacter smithii, are not bacteria at all but archaea. They consume hydrogen and produce methane. Methane is not an inert gas: it slowed intestinal transit and increased non-propulsive contractions in experimental work [21].
In a meta-analysis, a positive methane breath test was associated with about 3.5 times the odds of constipation, in both IBS and functional constipation [22]. This is an association. Slow transit also gives methanogens more time to grow, so the relationship probably runs both ways. Because methanogens can live throughout the bowel, the American College of Gastroenterology now calls this intestinal methanogen overgrowth (IMO), defined by breath methane of 10 ppm or more [24,25].
Hydrogen sulfide
At the other end of the spectrum, hydrogen sulfide-producing bacteria such as Desulfovibrio and Fusobacterium have been associated with diarrhoea-predominant IBS. A study combining breath gases with stool sequencing found methane producers dominated in IBS-C and hydrogen sulfide producers in IBS-D [23]. This work comes largely from one research group, and hydrogen sulfide breath testing is still new. For now this is an emerging association, not an established cause.
Small intestinal bacterial overgrowth (SIBO)
SIBO is found more often in IBS than in healthy people in case-control studies [26]. It is real and treatable, but breath tests can over-call it, as noted above [9]. I test for SIBO when the story fits, such as previous bowel surgery, slow motility, or bloating that starts soon after eating [24].
Bile acids: a major, under-recognised driver
Bile acids are made in the liver, released into the gut to digest fat, and about 95% are normally reabsorbed at the end of the small bowel. The rest reach the colon, where microbes convert primary bile acids into secondary bile acids.
This matters for motility in both directions, and it is one of the least appreciated parts of IBS:
Too much bile acid reaching the colon causes diarrhoea. Some bile acids, such as chenodeoxycholic acid (primary) and deoxycholic acid (secondary), make the colon secrete fluid and trigger strong propulsive contractions [28]. About one in four to one in three people with IBS-D have bile acid malabsorption on SeHCAT testing, a scan used overseas but not available in Australia [27]. In a Swedish IBS cohort, those with bile acid malabsorption had faster colonic transit and more frequent stools [29].
Too little of the "right" bile acids can contribute to constipation. People with IBS-C have lower levels of the secretory primary bile acids and more lithocholic acid, a secondary bile acid that does not stimulate the colon [30]. Giving a primary bile acid, chenodeoxycholate, accelerated colonic transit in women with IBS-C [31].
The microbiome controls the switch from primary to secondary bile acids. Change the microbes, and you change the bile acid mix the colon sees. When oral vancomycin was given to men with metabolic syndrome, it reduced bacterial conversion of primary to secondary bile acids [32]. This is why bile acid metabolism is being studied as a possible treatment target (see Treatment).
Pillar 3: Diet – FODMAPs, fibre and the gluten question
Food changes motility in two main ways: by pulling water into the bowel, and by feeding fermentation. The right diet depends on whether your gut is too fast, too slow, or simply over-sensitive.
Low FODMAP: powerful, but a tool rather than a lifestyle
FODMAPs are short-chain carbohydrates that are poorly absorbed and rapidly fermented. In a Monash University trial, a low FODMAP diet reduced IBS symptoms compared with a typical Australian diet [33]. A network meta-analysis ranked it first among the diets tested for global IBS symptoms, although the certainty of evidence was low [34].
MRI studies show how different FODMAPs act on motility [35]:
Fructose (an excess in apples, pears and honey) draws water into the small bowel. This loosens stools and speeds transit.
Fructans such as inulin (wheat, onion, garlic) pass to the colon and are fermented, producing gas and distension.
Interestingly, people with IBS do not produce more gas than others after these sugars. They feel the same amount of gas more intensely [36]. This is visceral hypersensitivity at work, and it is why diet and the gut–brain axis are so closely linked.
A strict low FODMAP diet also lowers Bifidobacteria, a beneficial group of gut bacteria [37]. I therefore use it in three phases with a dietitian: a short restriction (2–6 weeks), structured reintroduction, then a personalised long-term diet that is as broad as possible.
Fibre: soluble versus insoluble
Not all fibre is equal, and the wrong type is a common reason IBS worsens.
Fibre type | Examples | Effect on the gut | Best for |
Soluble, viscous, low-fermenting | Psyllium | Holds water and forms a gel: softens hard stool and firms loose stool | Most IBS subtypes, especially IBS-C |
Soluble, highly fermentable | Inulin, FOS, chicory root | Rapid fermentation produces gas and distension | Use cautiously; often poorly tolerated |
Insoluble | Wheat bran, skins and seeds | Adds bulk and speeds transit, but often worsens bloating and pain | Generally avoid in IBS |
The trials agree. In a meta-analysis, soluble fibre improved IBS symptoms (number needed to treat 7), while bran did not [38]. In a primary care trial, psyllium reduced symptom severity, while bran was linked to more early drop-outs because symptoms got worse [39].
Whole foods help too. Eating two green kiwifruit a day increased complete bowel movements in IBS-C in an international randomised trial [40].
Gluten or fructan?
Many patients feel better off wheat and assume gluten is the culprit. Often it is the fructan in wheat instead. Once FODMAPs were reduced, gluten caused specific symptoms in only 8% of people with self-reported gluten sensitivity [41]. In a blinded crossover trial, fructan, not gluten, triggered symptoms [42].
Gluten is not always innocent. In IBS-D, gluten increased stool frequency and small bowel permeability compared with a gluten-free diet, particularly in people carrying the coeliac genes HLA-DQ2/8 [43]. Coeliac disease must always be excluded with blood tests before you cut out gluten, because a gluten-free diet makes the tests unreliable.
Pillar 4: Visceral hypersensitivity and the gut–brain axis
Visceral hypersensitivity means the nerves of the gut, and the brain that interprets them, turn normal signals up too loud. A normal amount of gas or stretch is felt as pain, bloating or urgency. This is a real, measurable change in nerve signalling. It does not mean the symptoms are "in your head". I often describe it to patients as the volume knob on the gut being turned up too high.
Visceral hypersensitivity matters. Across five patient cohorts in different countries, the more sensitive the gut, the more severe the symptoms. This held even after accounting for anxiety and depression [44]. It also explains why people with IBS feel normal gas volumes more intensely, as described in the diet section [36].
The gut–brain axis runs both ways
The gut and brain are in constant two-way communication through nerves, hormones, immune signals and microbial chemicals. The 12-year Australian study described earlier showed that anxiety can predict new gut symptoms, and gut symptoms can predict new anxiety [7].
What can switch hypersensitivity on
Gastroenteritis. More than 10% of people develop IBS after an infectious gastroenteritis, about four times the usual risk [45].
Immune activation and mast cells. Activated mast cells sitting close to gut nerves correlate with how much pain people with IBS experience [46]. In mice, a gut infection can trigger a local allergic-type (IgE) response to ordinary food proteins, which then drives mast cell activation and meal-related pain via histamine. In people with IBS, injecting food proteins into the bowel lining caused local swelling and mast cell activation [47].
Abnormal reflexes in bloating. Visible abdominal distension is often not excess gas. The diaphragm pushes down while the abdominal wall relaxes, and this reflex can be retrained with biofeedback [48].
Clues that this pillar is dominant
Pain or bloating is the main complaint while bowel habit is near normal. Symptoms flare with stress or poor sleep. People often have other sensitivity conditions, such as migraine, fibromyalgia or reflux hypersensitivity. Motility tests are often normal. In these patients, treating the nerves is often more effective than chasing the bowel habit.
IBS treatment options: matching the therapy to the mechanism
Treatment works best when it targets the pillar driving your symptoms. A treatment that helps one person can make another worse. Fibre, for example, helps slow transit but can worsen bloating in visceral hypersensitivity.
Pillar | Main options | What the evidence shows |
Slow motility (IBS-C) | Macrogol, linaclotide, prucalopride, pelvic floor biofeedback | Secretagogues improve both pain and bowel habit [49,51] |
Fast motility (IBS-D) | Bile acid binders, ondansetron, loperamide | Ondansetron improves urgency and stool form [54] |
Microbiome | Rifaximin, rifaximin plus neomycin for methane, selected targeted antibiotics | Rifaximin gives adequate relief in about 4 in 10 [57] |
Diet | Soluble fibre, low FODMAP with reintroduction, kiwifruit | Low FODMAP ranks top among diets [34] |
Visceral hypersensitivity | Low-dose amitriptyline, gut-directed hypnotherapy, CBT | Both amitriptyline and hypnotherapy have strong trial evidence [63,65] |
1. Modulating motility
When the gut is too slow. Soluble fibre and macrogol (PEG 3350) are first-line. Macrogol reliably improves constipation in IBS-C, but not pain [53]. Linaclotide, a secretagogue that draws fluid into the bowel, improves both bowel habit and abdominal pain [51]. In Australia, linaclotide is not routinely available. It is generally accessed through a compounding pharmacy on a specialist's prescription, and the regulatory requirements depend on how it is supplied. A network meta-analysis confirmed the benefit of secretagogues in IBS-C [49]. Prucalopride, a 5-HT4 prokinetic, speeds colonic transit and is effective in chronic constipation [52]. If straining and incomplete emptying point to pelvic floor dyssynergia, biofeedback physiotherapy treats the cause [15].
When the gut is too fast. Loperamide helps urgency and frequency on bad days. The anti-nausea drug ondansetron, a 5-HT3 blocker, firmed stools and reduced urgency and frequency in IBS-D, though it did not reduce pain [54]. Bile acid binders (cholestyramine, colestipol, colesevelam) can be very effective for bile acid diarrhoea. SeHCAT testing is not available in Australia, so I usually use a trial of cholestyramine. A clear response supports the diagnosis and treats it at the same time, although a lack of response does not completely rule it out. In pooled, mostly uncontrolled data, response reached 96% in people with the most severe bile acid malabsorption [27]. A network meta-analysis compares the main IBS-D drugs [50].
For cramping pain. Antispasmodics and peppermint oil help some people [55]. In a large Dutch trial, peppermint oil missed its main endpoint but reduced abdominal pain [56].
2. Targeting the microbiome
SIBO and IBS without constipation. In two large trials, a two-week course of rifaximin gave adequate relief of IBS symptoms and bloating in about 41% of patients, compared with 32% on placebo [57]. Rifaximin is minimally absorbed. In Australia it is not PBS-subsidised for IBS.
Methane (IMO) and constipation. Rifaximin alone often fails to clear methane. In a retrospective study, rifaximin plus neomycin cleared breath methane in 87% of patients, compared with 28% for rifaximin alone [58]. Clearing methane on a breath test is not the same as lasting symptom relief.
Targeting bile acid metabolism (experimental). This is a research hypothesis, not an established treatment for IBS. Some antibiotics, such as oral vancomycin, act mainly on the bacteria that convert primary into secondary bile acids [32]. In theory, this could shift the colon's bile acid mix towards one that stimulates secretion and propulsion [28,31]. The scientific interest is that changing how microbes handle bile acids might one day offer a treatment target for a subset of people with refractory constipation. The clinical evidence is limited. A small 1995 trial of eight patients found they felt better, but measured transit did not change, and one patient stayed in remission [59]. Antibiotics also carry real risks: disruption of the healthy microbiome, C. difficile infection, and antimicrobial resistance, including vancomycin-resistant enterococci (VRE). For these reasons it is not a standard treatment. At most, it might be discussed case by case after standard options have failed, with full disclosure of the uncertainty and the risks.
Faecal microbiota transplantation (FMT). FMT is established for recurrent C. difficile infection, but results in IBS are inconsistent. One trial using a carefully selected donor reported responses in up to 89% [60]. Another found a benefit at three months [62]. A capsule trial found placebo did better [61]. The British guideline recommends against FMT for IBS outside research [4], and I agree.
3. Diet
Diet therapy follows the motility type and the fermentation story:
Psyllium for most patients, especially those with constipation. Avoid wheat bran [38,39].
Low FODMAP diet for bloating, gas and loose stools. Always use a short restriction, then reintroduction and personalisation with a dietitian [33,34,37].
Two green kiwifruit daily for IBS-C [40].
Use a structured re-challenge with a dietitian to tell fructan from gluten, and exclude coeliac disease first [41,42].
4. Calming the gut–brain axis
Low-dose amitriptyline. Amitriptyline is used here as a nerve modulator, not as an antidepressant, at a fraction of the antidepressant dose. In the ATLANTIS trial of 463 patients in UK general practice, low-dose amitriptyline titrated from 10 mg to a maximum of 30 mg was superior to placebo and well tolerated [63].
Gut-directed hypnotherapy. This is a structured, evidence-based therapy that teaches the brain to turn down gut signals. Hypnotherapy has helped IBS since the first controlled trial in 1984 [64]. In a Monash trial, hypnotherapy and the low FODMAP diet produced similar symptom improvements lasting at least six months, and hypnotherapy improved anxiety more [65]. A network meta-analysis found gut-directed hypnotherapy and CBT had the strongest evidence among psychological therapies [66]. Hypnotherapy is now widely available in Australia, including through app-based programs.
Practical summary: what to do next
You don't need to do everything at once. Here is what I suggest, in order.
Start this week
Keep a two-week symptom diary. Record stool form (Bristol scale), frequency, urgency, pain, bloating, meals, stress and sleep. It answers "fast, slow or normal?" better than most tests, and it makes your appointment far more productive.
Start psyllium, slowly. Take 1 teaspoon a day in a full glass of water, building over 2–3 weeks to about 10 g a day, the dose used in the main trial [39]. Avoid wheat bran [38].
If you are constipated, add two green kiwifruit a day [40].
Move more. Aim for 20–60 minutes of moderate activity on 3–5 days a week. In a Swedish randomised trial, increasing physical activity improved IBS symptoms [67].
Don't go gluten-free or start a strict diet on your own. Have a coeliac blood test first, and do a low FODMAP diet with an Accredited Practising Dietitian [33,41,42].
Match your next step to your symptoms
If this sounds like you | Start with | Ask your doctor about |
Hard, infrequent stools, straining | Psyllium, kiwifruit, macrogol | X-ray marker study, anorectal manometry, pelvic floor biofeedback, linaclotide or prucalopride, methane breath test |
Loose, urgent stools | Psyllium, loperamide on bad days, smaller lower-fat meals | A trial of cholestyramine, ondansetron, rifaximin |
Bloating and wind | Low FODMAP for 2–6 weeks with a dietitian, then reintroduce foods | A breath test if your history fits; retraining for visible distension |
Pain is the main problem | Peppermint oil, regular activity, sleep and stress management | Low-dose amitriptyline, gut-directed hypnotherapy or CBT |
See a doctor promptly if you have
Rectal bleeding, unintended weight loss, anaemia, symptoms that wake you at night, fever, a new change in bowel habit in middle age or later, or a family history of bowel cancer, IBD or coeliac disease.
When to see a gastroenterologist
Your symptoms persist after three months of first-line steps.
You are not sure whether your gut is fast, slow or simply sensitive.
You have been told "it's just IBS" and left without a plan.
IBS is rarely fixed by a single tablet. But once the mechanism is clear, many people achieve meaningful, lasting improvement, although responses vary and symptoms can return. That is the goal of every IBS consultation I do at Shore Gastroenterology, on Sydney's North Shore and Northern Beaches.
This article is general information and is not a substitute for individual medical advice. Please discuss any change in treatment with your own doctor.
Frequently asked questions
What should I do after being diagnosed with IBS?
Treat the diagnosis as a starting point. Keep a two-week symptom diary, start a soluble fibre such as psyllium, stay active, and work out with your doctor whether your gut is fast, slow or normal speed. Treatment can then target the mechanism driving your symptoms, not just the label.
Do I need a colonoscopy if I have IBS?
Not usually. IBS can be diagnosed confidently from your history, an examination and a few blood and stool tests. Colonoscopy is for red flags such as bleeding, weight loss, anaemia, a family history of bowel cancer or IBD, or a new change in bowel habit in middle age or later. [4,5]
Are breath tests useful for IBS?
Sometimes. A breath test can help when your history suggests methane-related constipation or bacterial overgrowth, but a hydrogen rise can also reflect the test sugar reaching the colon rather than true small bowel overgrowth. It is best ordered to answer a specific question. [9]
Is it gluten or FODMAPs that upsets my gut?
Often it is the fructan in wheat, a type of FODMAP, rather than gluten. Have a coeliac blood test before cutting out gluten, and use a structured re-challenge with a dietitian to work out your triggers. [41,42]
What is the most effective treatment for IBS?
There is no single best treatment, because IBS has different drivers. Options include soluble fibre, a dietitian-led low FODMAP diet, bile acid binders, secretagogues such as linaclotide, low-dose amitriptyline and gut-directed hypnotherapy, chosen according to whether your gut is fast, slow or over-sensitive. [34,49,63,65]
When should I see a gastroenterologist for IBS?
See a gastroenterologist if your symptoms persist after about three months of first-line steps, if you are unsure what is driving them, or if you have any red-flag symptoms. I see patients with IBS at Shore Gastroenterology on Sydney's North Shore and Northern Beaches.
Related reading
References
All references were checked against PubMed on 19 November 2026.
[1] Ford AC, Sperber AD, Corsetti M, et al. Irritable bowel syndrome. Lancet. 2020;396(10263):1675-1688. doi:10.1016/S0140-6736(20)31548-8
[2] Corsetti M, Shin A, Lacy BE, et al. Bowel Disorders (Rome V). Gastroenterology. 2026;170(6):1261-1282. doi:10.1053/j.gastro.2026.02.003
[3] Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(8):956-62.e1. doi:10.1016/j.cgh.2012.12.038
[4] Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. doi:10.1136/gutjnl-2021-324598
[5] Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036
[6] Mars RAT, Yang Y, Ward T, et al. Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome. Cell. 2020;182(6):1460-1473.e17. doi:10.1016/j.cell.2020.08.007
[7] Koloski NA, Jones M, Kalantar J, et al. The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61(9):1284-90. doi:10.1136/gutjnl-2011-300474
[8] Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-54. doi:10.1038/ajg.2015.6
[9] Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60(3):334-40. doi:10.1136/gut.2009.205476
[10] Manabe N, Wong BS, Camilleri M, et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil. 2010;22(3):293-e82. doi:10.1111/j.1365-2982.2009.01442.x
[11] Ford AC, Marwaha A, Lim A, et al. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8(5):401-9. doi:10.1016/j.cgh.2009.07.020
[12] Törnblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol. 2012;107(5):754-60. doi:10.1038/ajg.2012.5
[13] Metcalf AM, Phillips SF, Zinsmeister AR, et al. Simplified assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40-7. doi:10.1016/0016-5085(87)90837-7
[14] Goyal O, Bansal M, Sood A. Clinical and anorectal manometry profile of patients with functional constipation and constipation-predominant irritable bowel syndrome. Indian J Gastroenterol. 2019;38(3):211-219. doi:10.1007/s12664-019-00953-8
[15] Chiarioni G, Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130(3):657-64. doi:10.1053/j.gastro.2005.11.014
[16] Pittayanon R, Lau JT, Yuan Y, et al. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019;157(1):97-108. doi:10.1053/j.gastro.2019.03.049
[17] Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512-9, e114-5. doi:10.1111/j.1365-2982.2009.01427.x
[18] Sun Q, Jia Q, Song L, et al. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(7):e14513. doi:10.1097/MD.0000000000014513
[19] Fukumoto S, Tatewaki M, Yamada T, et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284(5):R1269-76. doi:10.1152/ajpregu.00442.2002
[20] Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264-76. doi:10.1016/j.cell.2015.02.047
[21] Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1089-95. doi:10.1152/ajpgi.00574.2004
[22] Kunkel D, Basseri RJ, Makhani MD, et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56(6):1612-8. doi:10.1007/s10620-011-1590-5
[23] Villanueva-Millan MJ, Leite G, Wang J, et al. Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes. Am J Gastroenterol. 2022;117(12):2055-2066. doi:10.14309/ajg.0000000000001997
[24] Pimentel M, Saad RJ, Long MD, et al. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-178. doi:10.14309/ajg.0000000000000501
[25] Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775-784. doi:10.1038/ajg.2017.46
[26] Shah A, Talley NJ, Jones M, et al. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Am J Gastroenterol. 2020;115(2):190-201. doi:10.14309/ajg.0000000000000504
[27] Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7):707-17. doi:10.1111/j.1365-2036.2009.04081.x
[28] Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332-9. doi:10.5009/gnl14397
[29] Bajor A, Törnblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 2015;64(1):84-92. doi:10.1136/gutjnl-2013-305965
[30] Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(10):1270-1275.e1. doi:10.1016/j.cgh.2013.04.020
[31] Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139(5):1549-58, 1558.e1. doi:10.1053/j.gastro.2010.07.052
[32] Vrieze A, Out C, Fuentes S, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014;60(4):824-31. doi:10.1016/j.jhep.2013.11.034
[33] Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5. doi:10.1053/j.gastro.2013.09.046
[34] Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71(6):1117-1126. doi:10.1136/gutjnl-2021-325214
[35] Murray K, Wilkinson-Smith V, Hoad C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol. 2014;109(1):110-9. doi:10.1038/ajg.2013.386
[36] Major G, Pritchard S, Murray K, et al. Colon Hypersensitivity to Distension, Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in Individuals With Irritable Bowel Syndrome. Gastroenterology. 2017;152(1):124-133.e2. doi:10.1053/j.gastro.2016.09.062
[37] So D, Loughman A, Staudacher HM. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. Am J Clin Nutr. 2022;116(4):943-952. doi:10.1093/ajcn/nqac176
[38] Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367-74. doi:10.1038/ajg.2014.195
[39] Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi:10.1136/bmj.b3154
[40] Gearry R, Fukudo S, Barbara G, et al. Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled Trial. Am J Gastroenterol. 2023;118(6):1058-1068. doi:10.14309/ajg.0000000000002124
[41] Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320-8.e1-3. doi:10.1053/j.gastro.2013.04.051
[42] Skodje GI, Sarna VK, Minelle IH, et al. Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity. Gastroenterology. 2018;154(3):529-539.e2. doi:10.1053/j.gastro.2017.10.040
[43] Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5):903-911.e3. doi:10.1053/j.gastro.2013.01.049
[44] Simrén M, Törnblom H, Palsson OS, et al. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut. 2018;67(2):255-262. doi:10.1136/gutjnl-2016-312361
[45] Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042-1054.e1. doi:10.1053/j.gastro.2016.12.039
[46] Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693-702. doi:10.1053/j.gastro.2003.11.055
[47] Aguilera-Lizarraga J, Florens MV, Viola MF, et al. Local immune response to food antigens drives meal-induced abdominal pain. Nature. 2021;590(7844):151-156. doi:10.1038/s41586-020-03118-2
[48] Barba E, Burri E, Accarino A, et al. Abdominothoracic mechanisms of functional abdominal distension and correction by biofeedback. Gastroenterology. 2015;148(4):732-9. doi:10.1053/j.gastro.2014.12.006
[49] Black CJ, Burr NE, Quigley EMM, et al. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. Gastroenterology. 2018;155(6):1753-1763. doi:10.1053/j.gastro.2018.08.021
[50] Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020;69(1):74-82. doi:10.1136/gutjnl-2018-318160
[51] Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-12. doi:10.1038/ajg.2012.254
[52] Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344-54. doi:10.1056/NEJMoa0800670
[53] Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-15. doi:10.1038/ajg.2013.197
[54] Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617-25. doi:10.1136/gutjnl-2013-305989
[55] Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. doi:10.1136/bmj.a2313
[56] Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2020;158(1):123-136. doi:10.1053/j.gastro.2019.08.026
[57] Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. doi:10.1056/NEJMoa1004409
[58] Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547-50. doi:10.1097/MCG.0b013e3181c64c90
[59] Celik AF, Tomlin J, Read NW. The effect of oral vancomycin on chronic idiopathic constipation. Aliment Pharmacol Ther. 1995;9(1):63-8. doi:10.1111/j.1365-2036.1995.tb00353.x
[60] El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859-867. doi:10.1136/gutjnl-2019-319630
[61] Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115. doi:10.1136/gutjnl-2018-316434
[62] Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. doi:10.1016/S2468-1253(17)30338-2
[63] Ford AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773-1785. doi:10.1016/S0140-6736(23)01523-4
[64] Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet. 1984;2(8414):1232-4. doi:10.1016/s0140-6736(84)92793-4
[65] Peters SL, Yao CK, Philpott H, et al. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(5):447-59. doi:10.1111/apt.13706
[66] Black CJ, Thakur ER, Houghton LA, et al. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441-1451. doi:10.1136/gutjnl-2020-321191
[67] Johannesson E, Simrén M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915-22. doi:10.1038/ajg.2010.480
[68] Sperber AD, Hreinsson JP, Simrén M, et al. Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study. Gut. 2026;75(10):1887-1897. doi:10.1136/gutjnl-2026-339666
[69] Staller K, Goodoory VC, Ng CE, et al. Epidemiologic, Clinical, and Psychological Characteristics of Individuals With Self-Reported Irritable Bowel Syndrome Based on the Rome V vs Rome IV Criteria. Clin Gastroenterol Hepatol. Published online July 30, 2026. doi:10.1016/j.cgh.2026.07.022



Comments